INVA vs SUPN
INVA: A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease platform (GIAPREZA, XACDURO, ZEVTERA, NUZOLVENCE). SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | INVA | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $21.30 | $46.98 | |
| Market cap as of 2026-07-31 | $1.6B | $2.7B | |
| P/E as of 2026-07-31 | 3.12 | n/a | |
| Net margin as of 2026-07-31 | +119.9% | -3.7% | INVA higher |
| Gross margin as of 2026-07-31 | +73.7% | +89.7% | SUPN higher |
| Operating margin as of 2026-07-31 | +38.1% | -7.8% | INVA higher |
| ROE as of 2026-07-31 | +47.6% | -2.7% | INVA higher |
| ROA as of 2026-07-31 | +32.4% | -2.0% | INVA higher |
| Debt / equity as of 2026-07-31 | 0.19 | 0.00 | SUPN lower |
| Revenue growth (YoY) as of 2026-07-31 | +13.8% | +16.3% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +2.5% | INVA higher |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-31 | 0.35 | 0.56 | |
| 1-year return as of 2026-07-27 close | +13.8% | +39.9% | SUPN higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.